Search Results 131-140 of 16977 for pharmacogenetics
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
About this study. The purpose of this study is to determine whether the implementation of pre-emptive PGx[HSR1] testing of a panel of clinically relevant ...
THe purpose of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a cohort of cancer ...
Now using pharmacogenomics testing, which looks at how a person's genetic traits affect their medication response, and a new gene verifier model, Dr. Diasio and ...
The purpose of this study is to establish an opioid and multiple addiction (OMA) biobank that creates a comprehensive standard patient phenotype using ...
About this study. A group of Mayo Clinic Biobank participants were genotyped for genetic variants as part of a separate study and a subset were found to be ...
An error occurred, please try again later. Copy for customer care: session ID undefined. Try again. Share · Tweet . VID-20423891.
Efforts are ongoing to identify response biomarkers by applying multiple omics. This includes genomics, transcriptomics, epigenomics, metabolomics and ...
Dasburg Professor in Cancer Genomics Research at Mayo Clinic in Rochester. He is a pioneer in pharmacogenetics, and his continuing translational work in ...
ROCHESTER, Minn. — Photon therapy offers strong outcomes in treating oropharyngeal cancers; however, some radiation can reach and damage nearby healthy tissue.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.